Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desoxycorticosterone pivalate is a long-acting synthetic mineralocorticoid hormone and an analog of desoxycorticosterone. It is primarily used as a replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease). The drug mimics the effects of endogenous aldosterone by increasing sodium retention and promoting potassium excretion in the kidneys. Mechanistically, it acts as an agonist at the mineralocorticoid receptor; after binding to this receptor, it forms a steroid-receptor complex that translocates to the nucleus and induces transcription of specific proteins responsible for electrolyte balance. Desoxycorticosterone pivalate has little or no glucocorticoid activity and should be used alongside appropriate glucocorticoid therapy when treating Addison’s disease[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desoxycorticosterone pivalate.